AutoPap marketing costs increase NeoPath's loss
This article was originally published in Clinica
NeoPath (US) recorded sales of $374,000 in the first quarter of 1996, $350,000 of which were for its AutoPap screening system in Australia. The company reported a net loss of $8.1 million on sales of $627,000 in the first half of 1996, compared with no revenues and a loss of $6.4 million for the same period in the previous year.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.